PRESS RELEASE published on 04/08/2024 at 23:00, 2 years 2 months ago Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Biophytis launches OBA phase 2 clinical study with BIO101 (20-hydroxyecdysone) for obesity treatment, targeting muscle preservation and promising results. Clinical program expected to start mid-2024 Biophytis Obesity Treatment BIO101 OBA Phase 2 Muscle Preservation
BRIEF published on 04/04/2024 at 23:05, 2 years 2 months ago Biophytis Announces Unanimous Approval in General Meeting Biophytis Shareholder Approval General Meeting RuvembriTM Age-related Diseases
PRESS RELEASE published on 04/04/2024 at 23:00, 2 years 2 months ago RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024 Biophytis announces all resolutions presented at the combined general meeting on April 2, 2024, have been adopted, including financial delegations. Shareholders' mobilization ensured a quorum of nearly 30% Shareholders Biophytis General Meeting Resolutions Approval
REGULATED PRESS RELEASE published on 04/04/2024 at 23:00, 2 years 2 months ago RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024 Biophytis announces approval of all resolutions at the Combined General Meeting held on April 2, 2024, with significant shareholder turnout. The Company specializes in therapeutics for age-related diseases Shareholders Biophytis Therapeutics Combined General Meeting Age-related Diseases
BRIEF published on 03/22/2024 at 07:05, 2 years 2 months ago Biophytis Unveils Phase 3 Sarcopenia Treatment Protocol Biophytis Clinical Research RuvembriTM Sarcopenia Phase 3 Study
PRESS RELEASE published on 03/22/2024 at 07:01, 2 years 2 months ago Biophytis presented its phase 3 protocol in the treatment of sarcopenia Biophytis presented its phase 3 protocol for treating sarcopenia with Ruvembri at ICFSR conference, showing promising results in phase 2 study Biophytis Ruvembri Phase 3 Protocol Sarcopenia Treatment ICFSR Conference
REGULATED PRESS RELEASE published on 03/22/2024 at 07:00, 2 years 2 months ago Biophytis presented its phase 3 protocol in the treatment of sarcopenia Biophytis presents phase 3 protocol for sarcopenia treatment at ICFSR conference, showcasing the potential of RuvembriTM. CEO Stanislas Veillet seeks partners for drug development and financing Biophytis RuvembriTM Clinical-stage Biotechnology Phase 3 Protocol Sarcopenia Treatment
BRIEF published on 03/18/2024 at 07:05, 2 years 2 months ago Biophytis Announces Combined General Meeting for April 2024 Biophytis RuvembriTM Clinical-stage Biotechnology Combined General Meeting Age-related Diseases
REGULATED PRESS RELEASE published on 03/18/2024 at 07:00, 2 years 2 months ago Combined General Meeting of April 2, 2024 Biophytis SA will hold its Combined General Meeting (CGM) on April 2, 2024 at Sorbonne Université, Paris. Shareholders can vote in advance. The company specializes in developing therapies for age-related diseases Therapeutics Combined General Meeting Biophytis SA Age-related Diseases CGM
BRIEF published on 03/15/2024 at 23:05, 2 years 2 months ago Biophytis Announces Reverse Stock Split on Euronext Growth Biophytis Biotechnology Shareholder Value Reverse Stock Split Euronext Growth
Published on 06/11/2026 at 18:01, 1 hour ago Kidoz Inc. Highlights Growing Importance of Advertising Without Personal Data Tracking Due to Age Verification Requirements
Published on 06/11/2026 at 15:20, 3 hours 41 minutes ago Fineqia Engages on Tokenization and Wallet Architecture Services for Club Coin Holdings
Published on 06/11/2026 at 15:00, 4 hours 1 minute ago Vox Royalty Notes Material Mine Life Extension and Expansion Studies at Bonikro Mine, Supporting +120,000oz Annual Production
Published on 06/11/2026 at 13:30, 5 hours 31 minutes ago RETRANSMISSION: CANEX Metals Acquires 100% of Gold Basin Resources
Published on 06/11/2026 at 13:00, 6 hours 1 minute ago Chow Tai Fook Jewellery Reports Record High Profit Brand Transformation Delivering High-quality Earnings Growth
Published on 06/11/2026 at 18:47, 13 minutes ago Fuller, Smith & Turner PLC: Director / PDMR Shareholding
Published on 06/11/2026 at 17:30, 1 hour 31 minutes ago GEVELOT S.A.: Press Release - Implementation of a share buyback program 11 June 2026
Published on 06/11/2026 at 17:00, 2 hours 1 minute ago EQS-WpÜG: Attainment of Control / Target company: Kontron AG; Bidder: ENNOCONN Corporation
Published on 06/11/2026 at 15:51, 3 hours 10 minutes ago PNE AG: Placement of the 2026/2031 corporate bond completed with a volume of EUR 36.0 million, coupon set at 7.000%
Published on 06/11/2026 at 17:45, 1 hour 16 minutes ago BAIKOWSKI: Annual General Meeting of June 11, 2026 - Dividend of €0.30 per share, to be paid out on June 30, 2026
Published on 06/11/2026 at 08:45, 10 hours 16 minutes ago Air Liquide and ArianeGroup renew strategic industrial partnership with two major Ariane 6 contracts
Published on 06/11/2026 at 08:30, 10 hours 31 minutes ago Aéroports de Paris S.A - €600 million new bond issue
Published on 06/10/2026 at 18:29, 1 day ago ICADE – PR – OUTCOME OF THE COMBINED GENERAL MEETING HELD ON JUNE 10 2026
